Semin Arthritis Rheu: Incidence and prevalence of cytomegaloblastitis and rheumatoid polymyalalygia.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- megacytosis (GCA; sometimes referred to as keratitis) and rheumatoid polymyalgia (PMR) are common and interrelated inflammatory diseases that affect almost exclusively in adults over the age of 50.needs up-to-date epidemiological information on these diseases.this systematic literature review (SLR) is intended to summarize the latest evidence on the incidence and prevalence of GCA and PMR.to retrieve articles published by PubMed and Google Academic Database prior to July 30, 2019.identified studies that reported the incidence and/or prevalence of GCA and/or PMR.use the latest if you have done multiple studies of the same population.system reviews detailed information on source populations and case validation.results are listed by region of the world.was screened by two authors and obtained 2,643 abstracts, 77 of which met the inclusion criteria.compared with PMR, GCA studies are more, and morbidity studies are higher than prevalence studies.there are very different studies in terms of research design and research population.studies that include detailed case validation tend to give lower estimates, especially for PMR.from Scandinavia and the United Kingdom (14.6-43.6) and The United States of America (19.8 per 100,000 population), the incidence of GCA per 100,000 population is highest.the corresponding estimate for southern Europe is lower (1.1-11.1).limited evidence that GCA and PMR are less common among non-Caucasian populations.white PMR was more than three times more likely to be estimated to be in the prevalence of PMR than GCA.the SLR provides the latest estimates of the incidence of GCA and PMR in different populations around the world.the incidence of GCA is higher in people of Nordic descent.data on PMR epidemiology are more limited, and estimates of morbidity and prevalence vary considerably..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.